Table I.
Characteristics of included studies.
| Author, year | Country | ECOG | Group | Interventional therapy details | mOS, months | N | Sex (M/F) | Age, years | Tumor size, cm | No. of tumors (single/multiple) | PVTT | Child-Pugh | BCLC | Data time frame | (Refs.) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ikeda, 2016 | Japan | 0-1 | SorCDDP | Cisplatin (65 mg/m2)/4–6 weeks | 10.6 | 65 | 56/9 | 49 (41–55) | 10.1 (7.7-13.2) | 30/95 | 40/25 | 5-6 | NA | June 2011-December 2013 | (25) |
| Sorafenib alone | 400 mg twice daily | 8.7 | 41 | 32/9 | 49 (40–56) | 10.1 (8.3-12.1) | 33/89 | 17/24 | |||||||
| Kudo, 2018 | Japan | 0-1 | Sorafenib + PF-HAIC | Cisplatin (20 mg/m2) on days 1 and 8 + 5-FU (330 mg/m2) on days 1–5 and 8–12/28 days | 11.8 | 102 | 89/13 | 69 (62–75) | NA | NA | 58/44 | 5-7 | 0/32/70 | November 2010-June 2014 | (24) |
| Sorafenib alone | 400 mg twice daily | 11.5 | 103 | 88/15 | 68 (62–75) | 64/39 | 0/27/76 | ||||||||
| Kondo, 2019 | Japan | 0-1 | SorCDDP | Cisplatin (65 mg/m2)/4–6 weeks | 15.2 | 35 | 28/7 | 72 (65–79) | NA | NA | 21/14 | 5-7 | 2/14/19 | August 2011-November 2014 | (23) |
| Sorafenib alone | 400 mg sorafenib twice daily | 10.0 | 33 | 27/6 | 70.9 (61.8-80) | 22/11 | 2/13/18 | ||||||||
| He, 2019 | China | 0-2 | Sorafenib + FOLFOX-HAIC | Oxaliplatin (85 mg/m2) + leucovorin (400 mg/m2) + 5-FU (400 mg/m2); 5-FU infusion 2,400 mg/m2 for 46 h/3 weeks | 13.4 | 125 | 111/14 | 49 (41–55) | 10.1 (7.7-13.2) | 30/95 | 125/0 | 5-6 | NA | April 2016-October 2017 | (22) |
| Sorafenib alone | 400 mg twice daily | 7.1 | 122 | 112/10 | 49 (40–56) | 10.1 (8.3-12.1) | 33/89 | 122/0 | |||||||
| Zheng, 2022 | China | 0-2 | Sorafenib + HAIC | Oxaliplatin (35 mg/m2) + 5-FU (600 mg/m2) + leucovorin (200 mg/m2 injected intravenously)/ 28 days | 16.3 | 32 | 30/2 | 56 (45–67) | 10.6 (6.6-14.6) | 15/17 | 32/0 | 5-7 | NA | June 2017-November 2019 | (21) |
| Sorafenib | 400 mg twice daily | 6.5 | 32 | 31/1 | 55 (45–65) | 10.7 (6.8-14.6) | 12/20 | 32/0 | |||||||
| Lee, 2020 | China | 0-2 | Sorafenib + TACE | Lipiodol + 10–20 mg Adriamycin/elution beads + Adriamycin/2–3 months | 11.0 | 27 | 23/4 | 60 (53-65.5) | 6.2 (3.5-13.5) | NA | 11/16 | 5-7 | NA | NA | (27) |
| Sorafenib | 200–400 mg twice daily | 5.0 | 17 | 15/2 | 59 (51–62) | 6.5 (3.4-12.5) | 5/12 | ||||||||
| Park, 2018 | South Korea | 0-2 | Sorafenib + TACE | Doxorubicin or cisplatin + embolization materials/28 days | 12.8 | 170 | 136/34 | 60.2 (50.6-69.8) | NA | NA | 68/102 | 5-7 | 3/39/128 | January 2013-December 2015 | (26) |
| Sorafenib | 200–400 mg twice daily | 10.8 | 169 | 147/22 | 61.3 (51.7-70.9) | 63/106 | 0/4/125 |
Continuous variables are expressed as median (range). ECOG, Eastern Cooperative Oncology Group; mOS, mean overall survival; PVTT, portal vein tumor thrombosis; BCLC, Barcelona Clinic Liver Cancer; SorCDDP, sorafenib with cisplatin-HAIC; HAIC, hepatic artery infusion chemotherapy; PF-HAIC, 5-FU-based HAIC; 5-FU, 5-fluorouracil; FOLFOX, 5-FU, leucovorin and oxaliplatin; TACE, transcatheter arterial chemoembolization; NA, not available.